Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood accounting for approximately 350 newly diagnosed cases yearly in the United States. With the development of multimodal chemotherapy regimens, relapse-free survival rates have improved to 70-80% in patients with localized disease albeit with significant toxicity. Unfortunately, despite aggressive treatment, patients with metastatic or recurrent disease continue to suffer from high mortality. Further characterization of the genetic events underlying this tumor type is critical for the development of more effective diagnostic, prognostic and therapeutic strategies. In a collaborative effort between the National Cancer Institute, the Children's Oncology Group, and the Broad Institute, we use a combination of whole-genome and whole-exome sequencing to characterize the landscape of somatic alterations in 147 tumor/normal pairs.

Authorized Access
Publicly Available Data
Study Inclusion/Exclusion Criteria

All specimens were obtained from patients with appropriate consent from the local institutional review board in accordance with the protocol of the Children' Oncology Group, the National Cancer Institute and the Broad Institute.

Molecular Data
TypeSourcePlatformNumber of Oligos/SNPsSNP Batch IdComment
Whole Exome Sequencing Thermo Fisher Scientific BFAST version 0.7.0a N/A N/A Agilent SureSelect 37.8 Mb capture
RNA Sequencing Illumina HiSeq 2500 N/A N/A
Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • Javed Khan, MD. National Institutes of Health, Bethesda, MD, USA.
  • Funding Source
    • National Cancer Institute. National Institutes of Health, Bethesda, MD, USA.